KLUS Pharma is currently seeking co-development partnerships to conduct clinical trials on COVID-19 patients in countries and regions most affected by the pandemic. Our investigational product (ACV200-17) is an inhaled peptide designed to prevent COVID-19 infection via respiratory transmission.
ACE2 protein is widely expressed in the human respiratory tract. Coronavirus SARS-CoV-2 infects human cells by binding to ACE2 on the cell surface via interaction with viral S protein. Results from both nonclinical and clinical studies have demonstrated that ACV200-17 could be a promising drug to prevent the further spread of COVID-19.
ACV200-17 blocks interactions between ACE2 and the viral S protein
Confirmed MOA and demonstrated efficacy in animal studies
Safety studies showed good tolerance in mice and monkeys when administered via intravenous and inhalation route
Demonstrated safety in healthy volunteers when given as single and repeated inhalation
The product is produced via GMP-certified manufacturing
KLUS Pharma is actively seeking collaboration opportunities to accelerate the development and commercialization of ACV200-17 in the US and EU, in order to help combat the spread of the current COVID-19 pandemic.
Business Development Team
KLUS Pharma Inc.
Cranbury, New Jersey, USA